Management continues to invest in the nutrition business and recently revealed plans to achieve 20% operating margin in nutrition over the next two years. In that regard, it does appear as if Abbott's international expansion plans in emerging markets are beginning to work, including goals to grow the percentage of total revenue in emerging markets from 40% today to roughly 50% by 2015.
To the extent that management can execute these plans while also growing profit margins, I believe this stock still has meaningful upside potential. But these are some big "ifs." Johnson & Johnson, Medtronic and, say, Boston Scientific (BSX) have expressed similar initiatives. I don't think they intend on ceding these growth opportunities without a fight.
On Wednesday, investors should tune in closely to the conference call to learn of these developments. Likewise, I believe Abbott can stabilize its stock and inject some confidence if management shores up the company's performance in its Established Pharmaceuticals business, or what the company calls "branded generics." If that that segment can show better than 2% growth, it would be an encouraging sign.
Listen, I like this company. I realize I've been a bit critical here. But it's because I see a lot of potential value that's not being realized. Some of which is due to weaknesses in execution where the likes of Johnson & Johnson have done moderately better.I do see opportunities for Abbott to steal market share in devices and diagnostics. It may require a strategic acquisition, or possibly two, for Abbott to gain the sort of leverage it needs to execute its global ambitions. While this recent pullback does make the stock appear more attractive, absent better growth and diversification, I'm still not at the point where I'd want to risk my own money here. At the time of publication, the author held no position in any of the stocks mentioned. Follow @saintssense This article was written by an independent contributor, separate from TheStreet's regular news coverage.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV